PSMA PET/CT was recently suggested as a suitable replacement for conventional imaging by providing superior accuracy compared to the combined findings of CT and bone scanning for staging patients with high-risk prostate cancer before a curative-intent treatment. This evidence concerns the gene FOLH1 and prostate carcinoma.